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Abstract
In 2007, the clinical and research profile of illusions, hallucinations, delusions and related 
symptoms in Parkinson disease (PD) was raised with the publication of a consensus definition of 
PD psychosis. Symptoms that were previously deemed benign and clinically insignificant were 
incorporated into a continuum of severity, leading to the rapid expansion of literature focusing on 
clinical aspects, mechanisms and treatment. Here, we review this literature and the evolving view 
of PD psychosis. Key topics include the prospective risk of dementia in individuals with PD 
psychosis, and the causal and modifying effects of PD medication. We discuss recent 
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developments, including recognition of an increase in the prevalence of psychosis with disease 
duration, addition of new visual symptoms to the psychosis continuum, and identification of 
frontal executive, visual perceptual and memory dysfunction at different disease stages. In 
addition, we highlight novel risk factors — for example, autonomic dysfunction — that have 
emerged from prospective studies, structural MRI evidence of frontal, parietal, occipital and 
hippocampal involvement, and approval of pimavanserin for the treatment of PD psychosis. The 
accumulating evidence raises novel questions and directions for future research to explore the 
clinical management and biomarker potential of PD psychosis.
In 2007, consensus recommendations from an international work group redefined the 
landscape of psychosis in Parkinson disease (PD)1. Symptoms of psychosis, such as 
illusions, hallucinations and delusions, are collectively referred to as ‘positive’, carrying the 
implication of an excess of function or brain activity, in contrast with ‘negative’ symptoms 
of deficit. Though all long recognized as nonmotor manifestations of PD, positive symptoms 
such as illusions, hallucinations and delusions were traditionally considered to be distinct 
from one another, with different clinical implications. In particular, hallucinations of a 
person, animal or indefinite object passing through the peripheral visual field (passage 
hallucinations), misperception of actual stimuli (illusions) and a distinct class of perceptual 
experiences without visual content but a ‘feeling’ of someone present (presence 
hallucinations) were not thought to carry the same clinical significance as formed visual 
hallucinations of animals, objects or figures. This distinction was reflected in the 
terminology, whereby illusions and passage and presence hallucinations were described as 
‘benign’ or ‘minor’ hallucinations.
After reviewing the available evidence, the combined National Institute of Neurological 
Disorders and Stroke (NINDS) and National Institute of Mental Health (NIMH) work group 
concluded that instead of representing distinct symptom classes, the various phenomena 
formed a continuum progressing over the course of PD. The typical clinical scenario was of 
minor phenomena evolving to formed visual hallucinations, with insight initially preserved 
but lost in later stages, and with delusions and non-visual — for example, auditory, tactile 
and olfactory — hallucinations also developing (BOX 1). This spectrum of positive 
symptoms was termed ‘PD psychosis’, and the proposed diagnostic criteria included the 
chronology of symptoms (occurrence after the onset of PD) and symptom duration 
(recurrent or continuous for 1 month). The NINDS–NIMH recommendations led to a 
paradigmatic shift in focus from individual positive symptoms to a symptom continuum, 
which was further characterized in a series of landmark reviews published in the years that 
followed2–8. These reviews benchmarked knowledge of PD psychosis in terms of its 
phenomenology, prevalence, clinical implications, mechanisms, treatment and future 
research directions, and led to a rapidly expanding literature. In this Review, we reflect on 
the advances that have been made in the 10 years since the publication of the consensus 
work group criteria, highlighting key research findings and directions in PD psychosis, and 
their implications for clinical practice and the neuroscience of PD.
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The psychosis spectrum in Parkinson disease
Positive symptoms in Parkinson disease (PD) vary across its course. Early in the disease, 
symptoms experienced include passage hallucinations (where a person, animal or 
indefinite object is seen briefly passing in the peripheral visual field), illusions (for 
example, seeing the branch of a tree as a cat), and presence hallucinations (a feeling that 
someone is nearby). Pareidolia refers to a specific class of illusion where faces and 
objects are seen in formless visual stimuli, such as clouds, flames or tree bark, or in 
geometric visual patterns, such as carpets or wallpaper. This type of illusion can occur as 
a normal perceptual experience, but is increased in frequency in PD159 and related 
disorders such as dementia with Lewy bodies.
Later in PD, formed visual hallucinations, typically of animals or people, occur. Insight 
— that is, recognition that the experiences are hallucinations — is preserved at this stage, 
but becomes lost as PD progresses, with the onset of false beliefs (delusions) and 
hallucinations in other sensory modalities (multimodality hallucinations). Cognitive 
decline and loss of insight parallel symptom progression, as illustrated by the transition in 
the arrow on the left from dark shading (cognition/insight intact) to light shading 
(cognition/insight impaired).
Approximate ratings of the Movement Disorder Society United PD Rating Scale (MDS-
UPDRS) hallucination/psychosis item are shown on the right of the figure, marking 
progression through different categories of experience on the continuum. The terms 
pseudohallucination and hallucinosis are used as synonyms for hallucinations with 
insight in some psychiatric and neurological traditions, but also have other meanings and 
were not adopted by the NINDS–NIMH work group1.
Phenomenology and diagnosis
As described by the NINDS–NIMH consensus work group1, symptoms of the psychosis 
spectrum in early stages of PD include minor experiences, such as passage and presence 
hallucinations, illusions, and formed hallucinations — most commonly, recurring visual 
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hallucinations of people, animals or inanimate objects — with insight preserved (BOX 1). In 
later PD stages, delusions and hallucinations occur in other modalities, for example, auditory 
hallucinations consisting of a voice that may not be comprehensible9, or non-verbal sounds, 
such as steps or music10. The hallucinations tend to occur in conditions of low ambient 
stimulation, typically when the individual is alone in a quiet environment, are experienced 
several times a day, and last for seconds to minutes in the early stages of PD psychosis. 
Evidence that has emerged since the publication of the consensus work group 
recommendations has helped to further characterize the phenomenology of different PD 
psychosis stages, and their relationship with the progression of Lewy body pathology (BOX 
2).
Box 2
Psychosis spectrum progression and Braak stage
The fact that illusions, passage and presence hallucinations progress to formed visual 
hallucinations in Parkinson disease (PD) need not imply that they all have the same 
underlying mechanism. Evidence has emerged that minor hallucinations and formed 
visual hallucinations are associated with different sets of risk factors. For example, 
presence hallucinations have been linked to sleep regulation and somnolence scores, 
illusions are related to somnolence and motor severity scores160, and neurobiological 
explanations of passage hallucinations implicate dysfunctional brainstem eye movement 
control mechanisms and subcortical and cortical motion pathways, including dorsal 
stream areas in the visual parietal lobe105,161. Previous studies of visual hallucinations 
have linked visual parietal areas to hallucinations in the peripheral visual field162 (as 
described for passage hallucinations) and palinopsia (helping to account for palinparousia 
— recently decribed palinopsia-like presence hallucinations11), and subregions of the 
intraparietal sulcus are linked to eye movement control163. By contrast, formed visual 
hallucinations are associated with changes in cognition, visual function and affect160, 
probably reflecting cortical involvement in ventral occipitotemporal lobe regions162. The 
onset of minor hallucinations might even precede the development of motor symptoms28.
The difference in timing of and risk factors for minor hallucinations and formed visual 
hallucinations mirrors the Braak progression of Lewy body pathology from brainstem to 
forebrain systems systems164. This observation suggests that symptom progression along 
the PD psychosis continuum begins with isolated minor experiences, indicating brainstem 
pathology (pink shading in figure) and its wider impact on subcortical and cortical 
motion and eye movement control networks, including the visual parietal lobe (arrows — 
note that dysfunction within these cortical networks does not necessarily imply cortical 
Lewy body pathology (BOX 4)). Subsequent emergence of visual hallucinations with 
insight indicates basal forebrain involvement (orange shading) and its wider impact on 
cortical cholinergic projections (arrows), in particular, projections to the ventral 
occipitotemporal cortex. Finally, multimodality hallucinations, delusions and loss of 
insight indicate widespread cortical Lewy body pathology.
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Relationship between brain structure, function and neuropathology in PD 
psychosis
The relationship between different imaging biomarkers of Parkinson disease (PD) 
psychosis remains unclear. Areas of reduced posterior cortical metabolism40 overlap with 
areas of reduced activation in functional MRI (fMRI) studies125, so might reflect similar 
underlying functional alterations or a causal link (for example, an area of reduced 
metabolism might result in a reduced blood oxygen level-dependent (BOLD) signal). 
Likewise, regions of increased metabolic activity in the frontal cortex118, as identified in 
some studies, may relate to regions of increased frontal fMRI activation125.
One question that arises is why specific subregions of frontal, parietal, limbic and 
occipital lobes are altered in PD psychosis. Some regions with atrophic or metabolic 
change have shown increased Lewy body and/or amyloid and tau pathology in 
postmortem studies55–57. However, other regions, in particular the occipital cortex, have 
limited neuropathological load even in end-stage disease58, contrasting with atrophy and 
possible hypometabolism in imaging studies. Therefore, in vivo imaging changes may 
not simply reflect localized neuropathology, but have other causes, for example, loss of 
cholinergic or serotonergic cortical projections, leading to a specific distribution of 
receptor upregulation, functional alterations and, in the longer term, atrophy.
Early PD psychosis symptoms
According to a report on the largest series of PD patients with presence hallucinations to 
date, the ‘presence’ is seen as an unformed visual shadow or mist in up to one-third of cases, 
may or may not be recognizable, and can be a persistent or recurrent experience of someone 
who has just left the room (palinparousia)11. An online questionnaire administered to 
individuals with PD suggested an overall prevalence of 50% for presence and passage 
hallucinations (‘extracampine hallucinations’ was used as a collective term for both 
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experiences, although this differs from its classic usage), with individual prevalences of 25% 
for presence hallucinations and 46% for passage hallucinations12. Studies of formed 
hallucinations in PD have found an association between the cognitive profile and the type of 
hallucination experienced13: patients with PD whose typical hallucinations are of unfamiliar 
content (for example, unidentified figures) have more-profound deficits of inhibitory 
executive function than do patients with hallucinations that are recognized (for example, 
family members). Additional visual symptoms that are observed in the early stages of PD 
and might be considered to belong to the psychosis spectrum are listed in TABLE 1.
Later PD psychosis symptoms
As PD progresses, hallucinations in non-visual (auditory, tactile and olfactory) modalities 
occur alongside visual hallucinations. In one cohort of PD patients without hallucinations at 
baseline, 60% were experiencing hallucinations in multiple sensory modalities by 10 years 
of follow-up14,15. These non-visual hallucinations are not confined to end-stage PD 
dementia; they are also found in patients whose cognition is relatively intact (Mini-Mental 
State Examination (MMSE) score 24 or 25)16,17.
One study has estimated the prevalence of delusions in a PD clinical setting at 16%18, rising 
to 47% in the subset of patients with PD psychosis18. Of note, an earlier study of patients 
with PD psychosis taking part in a clinical trial indicated an even higher prevalence of 
delusions (76%)16. The delusional themes that are identified depend on the assessment 
instruments used, but they typically encompass sin or guilt, grandiosity, reference, religion, 
persecution, jealousy, and theft, without prominence of any specific theme16. Delusional 
mis-identification syndromes, a specific subset of delusions characterized by pathological 
familiarity, include the Capgras delusion (the belief that someone familiar has been replaced 
by an imposter), reduplicative paramnesia (the belief that a room or place has been 
duplicated and is present at two locations simultaneously) and the mirror sign (failure to 
recognize oneself in the mirror)19,20. In patients who have dementia with Lewy bodies 
(DLB), the prevalence of misidentification syndromes was found to increase with greater 
cognitive decline (40% for MMSE score >20 compared with 60% for MMSE score <10)21. 
A similar trend was observed in individuals with AD, although the prevalence was lower 
overall (18% for MMSE score >20 and 28% for MMSE score <10). A smaller-scale study of 
patients with PD dementia found a 16.7% prevalence of misidentification symptoms, and 
also noted an association between these symptoms and a specific profile of memory and 
language deficits20.
Assessment scales
Several scales to measure positive symptoms were available in 2007 (REF. 22), but none 
were specifically designed for use in PD. As a result, many of the studies reviewed here used 
a definition of psychosis spectrum status that was based on a single question item within the 
Movement Disorder Society United PD Rating Scale (MDS-UPDRS), with a range of 0–4 
(BOX 1). New scales have emerged to better capture the diversity of symptoms and for use 
in clinical trials, including the North-East Visual Hallucinations Interview (NEVH-I)23 and a 
shortened version of the Scale for Assessment of Positive Symptoms adapted for PD (SAPS-
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PD)24. A test to measure susceptibility to pareidolia has been developed for DLB25, and 
might also have a role in the assessment of early symptoms of PD psychosis.
Frequency and clinical consequences
As concluded by the NINDS–NIMH psychosis work group and related reviews, psychosis 
spectrum symptoms are common in PD and have important clinical consequences, in 
particular, an increased risk of dementia, nursing home placement and mortality. Quality of 
life is also impaired, both overall and in subdomains of emotional well-being, daily living, 
cognition and bodily discomfort26. Recent studies have provided revised prevalence 
estimates for PD psychosis based on longitudinal study data, and have better characterized 
the link to poor cognitive outcome.
Prevalence
In early cross-sectional studies, the prevalence of the psychosis spectrum varied depending 
on which symptoms were included, and which PD population was studied. For example, 
estimates of complex visual hallucinations ranged from 22–38%, compared with 0–22% for 
auditory hallucinations3. Prevalence estimates from older studies that excluded minor 
hallucinations required revision after the publication of the consensus guidelines27. 
According to the latest figures, minor phenomena are reported in 42% of patients with very 
early disease28, although this high estimate could reflect recall bias29. In a large-scale study 
(n= 250) that excluded patients with MMSE scores ≤23, the prevalence of PD psychosis was 
26%30.
Longitudinal studies conducted in the wake of the consensus guidelines have established that 
the prevalence of the psychosis spectrum is time dependent, increasing with the duration of 
PD3,31–33. In a study that used detailed phenomenological interviews31, 82.7% of patients 
experienced psychosis spectrum symptoms over a period of 36 months. In another study, 
which excluded minor hallucinations, 60% of patients had experienced psychosis spectrum 
symptoms by the end of a 12-year follow-up period33. The Parkinson’s Progression Markers 
Initiative (PPMI) reported an increase in the prevalence of psychosis from 3% around the 
time of PD diagnosis to 10% at 2 years’ follow-up32.
Risk of cognitive decline
An association between visual hallucinations and the subsequent emergence of dementia 
was first reported in 2003 (REF. 34). Patients who reported previous visual hallucinations at 
study entry had an increased risk of dementia at 8 years (OR 3.1, 95% CI 1.6–6.2). This 
association has been replicated in several recent studies of shorter follow-up duration. One 
study35 found that visual hallucinations and visual illusions at baseline had separate 
predictive effects for dementia at ~4 years, and another study36 found that the longitudinal 
emergence of visual hallucinations — that is, emergence across the duration of the study — 
increased the risk of dementia at ~6 years. The PRIAMO study of early PD found a decline 
in cognitive function at 2 years in patients with psychosis spectrum symptoms37. The 
detailed profile of cognitive decline over 1–2 years has been reported in prospective cohorts 
defined at baseline by the presence or absence of visual hallucinations38,39. A significant 
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group × time interaction was found, with a steeper decline across a range of cognitive 
domains and an increased risk of dementia at follow-up in patients with visual 
hallucinations. A recent metabolic imaging study of PD-associated mild cognitive 
impairment (PD-MCI) has also found elevated rates of dementia at 30-month follow-up in 
patients with visual hallucinations40.
Psychosis spectrum symptoms are not the sole predictors of future cognitive decline in PD: a 
range of factors have been identified, the interrelationship of which has yet to be clarified. 
According to multivariate analyses34,36, visual hallucinations are independent of other 
factors, but their predicitive statistical significance is reduced when cognitive measures are 
included36, suggesting that cognition and visual hallucinations are closely related.
Association with motor subtypes
Exploratory and confirmatory cluster analysis of a large PD data set revealed associations 
between non-tremor-dominant PD and psychopathology, including hallucinations and 
cognitive impairment41. The association between clinically defined non-tremor subtypes and 
dementia, but not the association with hallucinations, was replicated in a subsequent study42. 
This discrepancy between studies might be attributable to differences in methodology.
Mechanisms and risk factors
A range of possible mechanisms to explain the psychosis spectrum, including changes in 
visual function, sleep, medication effects and cognition, were identified by the NINDS–
NIMH work group and in related reviews, with unifying models being presented to 
summarize the proposed interrelationship between these mechanisms1–3.
The eye and low-level vision
The predominantly visual nature of PD psychosis spectrum symptoms points to dysfunction 
in the visual system, and early studies focused on low-level deficits in colour vision, contrast 
sensitivity and acuity (reviewed elsewhere2). More recently, evidence has emerged of retinal 
changes in PD, as measured by techniques such as ocular coherence tomography (OCT) and 
electroretinography43; however, to date, only one study using such techniques has 
investigated the retinal associations of the PD psychosis spectrum. In patients with visual 
hallucinations, OCT revealed thinning of the retinal ganglion cell layer in the dominant eye 
at both nasal and temporal retinal locations44. Such thinning could be the result of a primary 
process within the eye, or could be secondary to retrograde trans-synaptic degeneration 
caused by changes in the brain. Thinning was more pronounced in PD psychosis patients 
without dementia (as measured by MMSE score), pointing to a primary process within the 
eye.
Visual perception and cognition
Early studies of the psychosis spectrum focused on visual hallucinations, and included 
patients with a range of severity of what might now be termed PD-MCI. More-recent studies 
have concentrated on differences in cognitive profiles for specific symptom subtypes, and 
the cognitive profile of the psychosis spectrum at different stages of global cognitive 
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impairment. TABLE 2 shows a range of cognitive tests that have been repeated in different 
studies, although the same version of a given test is rarely used by different groups. Most 
studies investigating visual perception, irrespective of the selection criteria (for example, 
unselected PD-MCI cohorts versus participants selected for higher cognitive function) have 
shown deficits in the perception of objects, including faces. Similarly, most studies 
investigating executive function, as measured by the Stroop task, response inhibition and 
verbal fluency, have found deficits in patients with visual hallucinations.
Deficits in memory and related hippocampal function tests are found in PD patients with 
visual hallucinations, in both unselected PD-MCI and higher-function groups. These deficits 
withstand correction for MMSE score, depression and PD stage45. Some studies have 
reported deficits that are specific to visual — as opposed to verbal — memory46. Greater 
memory deficits have also been found for black-and-white visual stimuli than for coloured 
visual stimuli, perhaps reflecting more-limited encoding of visually impoverished stimuli in 
patients with visual hallucinations47. A transitive inference test thought to measure 
hippocampal function has uncovered impairments in patients with PD psychosis48.
TABLE 2 helps to illustrate agreement between studies regarding cognitive functions that 
are deficient, but it does not reveal whether some cognitive functions show relative sparing. 
Tests purporting to measure visuospatial function, such as the Benton judgement of line 
orientation and the Rey complex figure test, are often included in test batteries for PD 
psychosis, but tend not to show significant differences46,49 (although see Katzen et al.50 for 
evidence of deficits on the Benton test). The lack of consistent findings could be a test 
sensitivity issue, as other measures of visuospatial function — for example, the Visual 
Object and Space Perception (VOSP) number location subtest47,51 — have been shown to 
differ between patients with and without visual hallucinations. Tests examining motion, 
spatiotemporal aspects of visual perception, and eye movements in the PD psychosis 
spectrum have not been reported to date, but are of particular relevance given the 
hypothesized role of dysfunctional motion perception and eye movement control in passage 
and presence hallucinations.
Minor hallucinations—Only one study has focused on the cognitive profile associated 
with minor hallucinations in PD52. Compared with patients without psychosis spectrum 
symptoms, patients with minor hallucinations had no significant differences in verbal 
memory, verbal fluency or sustained attention. Progressive decreases in cognitive 
performance were seen across the spectrum from no hallucinations, through minor 
hallucinations and hallucinations with insight, to hallucinations without insight. The lack of 
cognitive deficits in patients with minor hallucinations raises the issue of whether the onset 
of psychosis spectrum symptoms predates measurable cognitive decline.
Multimodal hallucinations—One might expect patients with non-visual hallucinations in 
the later stages of PD to exhibit greater cognitive deficits or a different cognitive profile 
compared with PD patients with visual hallucinations alone. However, one study that 
compared patients with visual only and visual plus non-visual hallucinations50 found no 
evidence of significant additional decline in the latter group for any of the cognitive domains 
tested (including verbal memory and verbal fluency). The number of patients with 
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hallucinations in multiple modalities was small (n = 12), so the study might have been 
underpowered to detect such changes.
Delusions—Only one study has compared cognitive profiles between PD psychosis 
spectrum patients with hallucinations but not delusions and those with delusions but not 
hallucinations18. Cognitive profiles did not differ significantly between the two groups. 
Cognitive scores in a range of domains were found to correlate with the severity and number 
of hallucination modalities (for example, auditory, olfactory somatic and/or visual), but not 
with the severity and number of delusion modalities (for example, jealousy, grandiosity 
and/or religious delusions). These findings suggest that cognitive risk factors for 
hallucinations and delusions might differ. This view is supported by evidence from a study 
investigating risk factors for a specific delusion (delusional jealousy), where an association 
was found with dopamine agonist treatment but not dementia, in contrast to hallucinations, 
where an association was found with dementia but not dopamine agonist treatment53.
Neuropathology
Neuropathological studies provide important insights into the distribution of Lewy body 
pathology at different stages of the PD psychosis spectrum (BOX 2). The first study to report 
on this issue found significantly higher Lewy body load in the amygdala and 
parahippocampal gyrus in patients with visual hallucinations, half of whom met the 
clinicopathological criteria for PD and half of whom met the criteria for DLB54. Subsequent 
studies have replicated the finding of limbic pathology associated with visual 
hallucinations55,56, with increased pathology also found in other regions, including the 
superior and lateral frontal cortex (Brodmann area 8/9), inferior and lateral temporal cortex 
(Brodmann areas 20 and 21), inferior parietal cortex (Brodmann areas 39 and 40), and 
cingulate cortex (Brodmann area 24). Visual hallucinations are also linked to higher levels of 
amyloid and tau pathology in frontal, parietal and hippocampal areas57. Only one study has 
investigated the occipital lobe in patients with visual hallucinations: Lewy body and tau 
pathologies were found to be absent, and amyloid burden was rated as mild58.
Unlike patients with PD psychosis who have dementia, those without dementia do not have 
cortical Lewy body involvement. An early study of PD patients with visual hallucinations 
and MMSE scores >25 found increased Lewy body load in the basolateral nucleus of the 
amygdala, but only sparse Lewy bodies in the cortex and hippocampus59. Consistent with 
the lack of cortical involvement, a recent study has found no association between Lewy 
body, tau or amyloid pathology in frontal, parietal and temporal regions and visual 
hallucinations after controlling for dementia, but found strong associations with dementia 
after controlling for visual hallucinations58. Such findings suggest that the neuropathological 
changes underlying visual hallucinations are distinct from those underlying dementia.
Involvement of the cholinergic system in visual hallucinations is suggested by brainstem 
atrophy in the pedunculopontine nucleus60 and atrophy of the substantia innominata, which 
contains the nucleus basalis of Meynert46. The cause of the atrophy is unclear, as no 
association has been found between visual hallucinations and Lewy body, tau or amyloid 
load in the nucleus basalis of Meynert58.
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Patients with visual hallucinations exhibit abnormalities on a range of autonomic tests, 
including the tilt-table test, the Valsalva manouevre and cardiac 123I-
metaiodobenzylguanidine imaging, indicating sympathetic dysfunction61. In addition, 
autonomic dysfunction was found to be an independent risk factor for hallucinations (all 
modalities included) in PROPARK, a large-scale 5-year prospective study62. The same study 
also reported female sex as an independent risk factor62. REM sleep behaviour disorder 
(RBD) is also associated with visual hallucinations (recently reviewed elsewhere63), 
although the association is weak64, and the proportions of patients with visual hallucinations 
who do and do not have RBD are similar. Vivid dreams are associated with visual 
hallucinations after controlling for factors including PD duration, depression, anxiety and 
UPDRS scores65. Depression has been associated with hallucinations in PD2. The urinary 
concentration of the oxidative stress marker 8-hydroxydeoxyguanosine was found to 
correlate with the hallucination score (modality unspecified) after controlling for MMSE 
score, age, duration and UPDRS part 3 score66.
Dopamine agonists
The role of medication in PD psychosis was noted to be “the most controversial aspect of 
these criteria” in the 2007 consensus recommendations1. Clinical experience suggested that 
the onset of PD psychosis could be linked to medication onset and improved with dose 
reduction, but there was no evidence of a direct causal relationship between pharmacological 
treatments or medication dose and PD psychosis (for example, levodopa infusion did not 
induce hallucinations67), and PD psychosis was recognized to occur in unmedicated 
patients.
In the intervening years, the role of medication has received relatively little research 
attention. The lack of a direct causal role for medication is supported by a high prevalence of 
minor symptoms28 or visual hallucinations68 in drug-naive patients, and the finding that 
levodopa dose equivalence did not increase the risk of psychosis in some prospective 
studies14,31, including the PPMI cohort32. However, though failing to reach statistical 
significance, a link to medication is implied in the threefold increase in psychosis onset for 
patients starting dopamine replacement therapy in the PPMI study. Similarly, a large-scale 
prospective study identified elevated baseline levodopa dose as a risk factor for PD 
psychosis, with an odds ratio of 1.26 per 100 mg of dose equivalence increase33, and a 
prospective study of early PD (PRIAMO) found increased rates of dopamine agonist 
treatment in patients who went on to develop PD psychosis37. The PROPARK study also 
identified dyskinesia and levodopa equivalence measures as independent risk factors for PD 
psychosis62.
The NINDS–NIMH work group1 suggested “anti-parkinsons medication as a modifier rather 
than a necessary feature for the diagnosis of PD psychosis” to help reconcile the medication-
related and medication-independent viewpoints. Evidence that has since emerged supports 
this ‘modifier’ account, but highlights the need for further work in this area to clarify the 
relationship between dopamine replacement therapy and PD psychosis.
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A recent review of the genetics of psychotic symptoms in PD identified 26 published articles 
on this topic69. The most commonly studied genetic factor is the apolipoprotein E ε4 
(APOE*ε4) allele, although dopaminergic pathway genes have been the focus of a number 
of studies.
With regard to APOE*ε4, little evidence is available to suggest an association with 
psychotic symptoms in PD (only one of seven studies reported an association with visual 
hallucinations)70–76, a finding that is mirrored in the AD literature77. The extended 
microtubule-associated protein tau (MAPT) haplotype is less well studied in PD psychosis: 
an initial study reporting an association between visual hallucinations and the H1 haplotype 
was not replicated by a second larger study70,71. By contrast, an increasing body of evidence 
suggests that glucosylceramidase (GBA) mutations are associated with psychosis in 
PD78–80. Of note, the influence of GBA is not limited to psychosis: GBA, like APOE and 
MAPT, has been associated with cognition in PD, as well as faster progression to dementia 
and more-severe motor stages79,81. Any associations between psychosis and these three 
genes are perhaps most likely to be driven by fundamental disease processes, such as tau or 
Lewy body accumulation. Therefore, considering any associations with a particular 
symptom in isolation would be too narrow an approach. Specifically, it will be important to 
establish whether any subtypes of PD have a pattern of cognitive impairment that is more 
similar to AD and carries a relatively low risk of psychosis (which might be predicted by 
APOE), compared with an early dysexecutive syndrome and greater risk of hallucinations 
(as indicated by the pattern of association with GBA).
Consistent evidence links GBA, but not APOE, with psychosis in PD; however, findings 
related to other genes have been equivocal. Polymorphisms in dopaminergic pathway genes 
have been examined in 15 studies (BOX 3). Although there is some evidence of a 
relationship between polymorphisms in dopamine transporter and cholecystokinin genes and 
psychosis, the overall number of studies examining these associations is small, making it 
difficult to draw reliable conclusions. Research in serotonin (5-hydroxytryptamine, or 5-HT) 
pathway genes is limited to two studies82,83, but with the recent demonstration of efficacy of 
pimavanserin for the treatment of PD psychosis (see below), serotonergic genes or other 
genes in serotonergic signalling pathways may provide promising avenues for future 
research.
Box 3
Genetic risk factors for psychosis in Parkinson disease
GBA
Associated with an increased risk of psychosis in three studies78–80. One study including 
only two cases with hallucinations found no association165.
MAPT
Mixed findings: one positive association and one negative71,72.
APOE
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No association (in six of seven studies). The APOE*ε4 allele was associated with 
hallucinations within 5 years of diagnosis in one study70–76.
COMT
No association74,166.
SLC6A3 (also known as DAT1)
Mixed findings: two of three studies reported an association, one with the variable 
number tandem repeat and one with the 839C>T polymorphism167–169.
DRD2






Mixed findings: two of four studies show evidence of an association with CCK 45C>T, 




One study reported an increased risk associated with the LL genotype in a mixed Lewy 
body dementia sample82.
ACE
Mixed findings: one study reported a significant association with levodopa-induced 
psychosis, whereas another reported no association175,176.
HOMER1
Mixed findings: one study reported an association with the A allele, and a second 
reported an association with the G allele and a reduced risk of adverse effects of levodopa 
treatment177,178.
The genetic aetiology of psychosis in PD will be complex, and is likely to involve many 
genes each with a small effect size. As such, the most promising genetic approaches will 
probably be those that leverage genome-wide data, which has the advantage of full genome 
coverage and is not constrained by biases resulting from a priori hypotheses. In the broader 
literature, recent advances in the analysis of genome-wide data sets have uncovered genetic 
pleiotropy between clinically distinct diseases84,85. Moreover, analyses whereby biological 
pathways (for example, molecular, cellular, organ/system or disease) are constructed on the 
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basis of genomic data and tested for enrichment of single nucleotide polymorphisms in cases 
versus controls have shown promise in late-life depression86. These types of emerging 
techniques have clear applications in heterogeneous conditions such as PD, where questions 
surrounding the overlapping aetiology between psychosis across neurodegenerative diseases 
and psychiatric disorders remain unanswered. The increasing availability of larger, better-
characterized data sets will provide greater potential to conduct these more-sophisticated 
genetic analyses.
Explanatory models
Explanatory models of PD psychosis attempt to integrate risk factors into unifying accounts 
(reviewed elsewhere87). The Activation–Input–Modulation (AIM) model88 takes a 
dimensional approach to PD psychosis, with contributions from an activation factor (the 
level of arousal), an input factor (the spectrum of externally and internally driven visual 
percepts), and a modulation factor (neurotransmitter and medication effects). The activation 
factor may help to explain why hallucinations typically occur with low ambient stimulation. 
The Perception and Attention Deficit (PAD) model89 argues that the core mechanism of 
complex hallucinations is dysfunctional integration of perceptual and attentional processing, 
leading to the intrusion of generic representations (proto-objects) into perceptual 
consciousness. In the attentional control model90, the core pathology of PD psychosis is 
dysfunctional integration between three networks (dorsal attention network, ventral attention 
network and default mode network), with a failure to engage the dorsal attention network in 
the context of ambiguous visual input and the intrusion of default mode contents into 
perceptual consciousness90–92. This account is supported by evidence from PD patients with 
visual hallucinations or illusions of elevated strength of mental imagery93, attentional set-
shifting deficits94, altered resting state and task activation networks95, and increased 
functional connectivity in the default mode network96. A dopamine-based model of PD 
psychosis97 argues for abnormalities of biasing and gating access to a global workspace that 
is thought, according to some accounts, to underlie conscious experience.
These unifying models are informed by clinical associations — for example, the 
combination of visual perceptual and frontal executive deficits — that were recognized at 
the time that the models were formulated. As the range of risk factors increases, the question 
arises as to whether all risk factors are linked to the mechanisms underlying PD psychosis. 
Distinctions may need to be drawn between associations that are integral to the mechanisms 
of PD psychosis or its individual symptoms, and syndromic associations caused by the 
spread of PD pathology to neighbouring brain regions or to separate brain regions at a 
similar disease stage. Which associations and risk factors are integral to PD psychosis and 
which are syndromic associations is unclear at present, and such information will be pivotal 
to the development of novel treatment approaches.
Imaging and electrophysiology
The raised profile of PD psychosis, combined with developments in imaging methodology, 
has resulted in a rapidly advancing evidence base that helps to inform the risk factor and 
mechanistic accounts of the symptom spectrum.
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Despite methodological differences, structural imaging studies of visual hallucinations have 
yielded a number of consistent findings98–100. Several studies have reported atrophy in the 
visual cortex101–103 — broadly defined as extending into lateral and ventral 
occipitotemporal regions including the fusiform gyrus and visual parietal cortex 
(corresponding to dorsal and ventral visual streams) — although this finding is not 
univeral104. One study of PD patients with and without visual hallucinations (some patients 
had hallucinations in both visual and other modalities), matched for cognitive status, only 
detected atrophy in posterior cortical regions101, whereas another study of visual 
hallucinations, in which global cognition (MMSE score) was included as a covariate, found 
atrophy in frontal, hippocampal and thalamic regions46. A study focusing on minor 
hallucinations found atrophy in the midbrain, cerebellar vermis and visual parietal cortex, as 
well as areas of increased cortical volume in the limbic cortex and the posterior lobe of the 
cerebellum, which might be linked to compensatory mechanisms105. Studies that did not 
control specifically for cognition found atrophy of the hippocampal head106, frontal regions 
(particularly the lateral frontal cortex)103,107,108, cerebellum103 and lateral parietal cortex103 
in patients with visual hallucinations.
The distribution of atrophy described in the various studies is consistent with the profile of 
cognitive deficits found in PD psychosis (FIG. 1). At 30-month follow-up, patients who 
report visual hallucinations at baseline have greater progression of cortical atrophy within 
limbic, frontal and thalamic regions, and are more likely to have developed dementia38. The 
greater rate of atrophy and hypothesized progression from hippocampal head involvement to 
diffuse hippocampal atrophy in patients with visual hallucinations106 might account for the 
association between visual hallucinations and poor cognitive outcome.
Few studies have investigated white matter changes in PD psychosis. An early study found 
no differences with regard to a range of clinically defined white matter lesion indices in 
patients with and without visual hallucinations109. A more recent volumetric study described 
decreased white matter volume in occipital and parahippocampal regions103. Another study 
showed that the microstructural integrity of deep white matter, as measured by fractional 
anisotropy, was affected in PD psychosis (defined as the presence of perceptual errors, 
hallucinations in any modality, or delusions). When fractional anisotropy was compared 
across groups as an absolute measure or normalized to globus pallidus or substantia nigra 
values, reduced fractional anisotropy was detected within regions of interest in the occipital 
lobe, frontal lobe and cingulate gyrus, and deep to the left hippocampal head110.
Neurotransmitter imaging
Reduced dopamine transporter binding in the striatum in early PD, as measured by the 123I-
β-CIT tracer, is associated with an increased prospective risk of PD psychosis at 5 years 
(assessed using the UPDRS thought disorder item)111. It is unclear whether this binding 
reduction represents the underlying mechanism of the psychosis spectrum or is an indirect 
association, for example, reflecting more-extensive neurodegenerative involvement in PD 
psychosis.
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In a serotonergic imaging study that used the 5-HT2A receptor ligand 18F-setoperone, 
increased binding in ventral occipitotemporal regions and bilateral frontal cortex was 
identified in patients with visual hallucinations112. By contrast, a 5-HT1A receptor binding 
study in postmortem tissue found no association with visual hallucinations, although 5-HT1A 
binding was elevated in sublayers of the orbitofrontal, ventral temporal and motor cortex in 
patients with PD, irrespective of visual hallucinations113.
Metabolic and blood flow imaging
Occipital hypometabolism and reduced regional cerebral blood flow (rCBF) are 
characteristics of DLB114,115, and have been linked to visual hallucination severity116. 
Whether the same regions exhibit reduced metabolism and rCBF in PD psychosis is less 
clear. Metabolic imaging studies of PD patients with and without visual hallucinations have 
identified reductions in posterior metabolism that spare the occipital pole117 or primary 
visual cortex (data from table in Nagano-Saito et al.118). In addition to posterior metabolic 
deficits, one study found increased frontal metabolism in PD psychosis118. Another study 
found that posterior metabolic deficits were more pronounced in patients with visual 
hallucinations and cognitive impairment (defined by the K-MMSE cut-off score, the Korean 
version of the MMSE), but were also present in patients with K-MMSE scores above the 
threshold value119.
In contrast to spared occipital metabolism in the studies described above, a recent study of 
PD-MCI has found evidence of occipital hypometabolism in PD patients with visual 
hallucinations40. The hypometabolism did not differ between patients who did and did not 
subsequently develop dementia40. Evidence also exists of decreased posterior perfusion in 
‘medication-induced’ hallucinations (mostly visual) that would now be termed PD 
psychosis, with significant reductions of rCBF in the posterior temporo-occipital cortex but 
not in the occipital lobe120. Similarly, another study of visual hallucinations in PD found 
trend-level posterior perfusion deficits that spared occipital cortices121. A region of 
decreased perfusion outside the occipital lobe in the ventral temporal cortex (fusiform gyrus) 
became significant after controlling for confound covariates, as did a region of increased 
perfusion in the superior and middle temporal gyrus121.
In summary, consistent evidence points towards posterior changes in metabolism and 
perfusion in PD patients with visual hallucinations, but the presence or absence of 
involvement of the occipital lobe remains unclear.
Functional MRI
There is a paucity of data on brain changes occurring in PD at the time of a hallucination 
(capture studies). One functional MRI (fMRI) case study found a decrease in activity in 
visual areas coincident with visual hallucinations122. This decrease in occipital activity 
contrasts with evidence from eye disease, schizophrenia and induced visual hallucinations, 
which indicates that activity in visual areas increases at the time of visual hallucinations123. 
The PD case study also reported increased activity in the frontal lobe during the 
hallucinations122. Frontal activations are not found in eye disease and schizophrenia during 
hallucinations; however, another PD case report, in which a different technique was used 
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(single-photon emission CT with technetium-99m ethyl cysteinate dimer), documented 
frontal and anterior temporal increases in rCBF during visual hallucinations124. Contrasting 
findings of occipital increases or decreases and the presence or absence of frontal activations 
across clinical contexts may suggest differences in the underlying mechanisms of 
hallucinations.
Studies in which visual stimulation was used to probe cerebral activity have reported 
decreased activation in the parietal lobe, lateral occipitotemporal cortex125 and occipital 
cortex126 in PD patients with a history of visual hallucinations. An early fMRI study 
reported decreased activity in the primary visual cortex but increased activation in the visual 
association cortex127. In the frontal lobe, both activation increases125 and activation 
decreases126,128 have been reported in response to visual stimulation. The contrasting 
findings might relate to differences in the stimuli and tasks used.
Reduced occipital low frequency fluctuations have been found in the resting state in PD 
patients with a history of visual hallucinations129. These fluctuations are thought to be an 
indirect measure of cerebral glucose metabolism and local field potentials, supporting the 
idea of occipital hypometabolism in patients with PD who are susceptible to visual 
hallucinations. Increased connectivity between occipital and frontal regions, the striatum and 
the thalamus129 and greater co-activation of default mode network nodes in the posterior 
cingulate/precuneus and lateral frontal cortex are associated with susceptibility to visual 
hallucinations in PD96.
Electrophysiology
In PD patients with a history of visual hallucinations, the P100 component of visual evoked 
potentials in response to reversing checkerboard stimulation was found to be delayed130, as 
was the P300 component of a visual odd-ball task131. A delay in evoked potential latency 
has also been found in association with illusions and visual hallucinations in an immersive 
virtual reality environment following short-term PD medication deprivation132. The evoked 
potential delays might fall within the distribution of normal variation, however, as rates of 
retinal and cortical evoked measures categorized as normal or abnormal on the basis of 
normal population standard deviation cut-off values do not differ between patients with and 
without hallucinations132,133. Changes in cholinergic-related electrophysiological measures 
(short-latency afferent inhibition) associated with susceptibility to visual hallucinations in 
PD are consistent with a loss of cortical cholinergic input134.
Treatment
As outlined in previous reviews, treatment of PD psychosis includes psychological therapies, 
dose reduction of PD medication, and medication to treat psychosis symptoms1,2,135. 
TABLE 3 summarizes double-blind, placebo controlled trials in patients with PD psychosis, 
including trials of pimavanserin (a 5-HT2A inverse agonist) and memantine that have been 
published since this topic was last reviewed. For patients without prominent cognitive 
impairment, clozapine and pimavanserin have the best evidence of efficacy in PD psychosis. 
In patients with cognitive impairment and visual hallucinations, rivastigmine was found to 
reduce the Neuropsychiatric Inventory score (predominantly the agitation component) in a 
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secondary analysis, and unpublished evidence suggests efficacy of pimavanserin in PD 
psychosis with cognitive impairment. The clozapine and pimavanserin trials have indicated a 
therapeutic effect specific to hallucinations as a whole but, to date, no studies have reported 
a specific effect on visual hallucinations. No treatment trials targeting minor symptoms have 
yet been reported.
Atypical antipsychotics
Evidence for the efficacy of clozapine in PD psychosis136–138 sparked interest in the 
potential efficacy of quetiapine, a structurally related compound. Although early studies 
suggested a beneficial effect of quetiapine, several subsequent studies failed to replicate the 
findings in PD139,140 and across the spectrum of dementia with parkinsonian symptoms141. 
Similarly, open-label studies suggested that olanzapine was efficacious for PD psychosis, but 
placebo-controlled142 and comparative143 trials found a worsening of motor symptoms 
without significant improvement of hallucinations. The 2011 Movement Disorder Society 
evidence-based medicine review of treatments for nonmotor symptoms concluded that there 
was insufficient evidence on the efficacy of quetiapine, and that olanzapine carried 
unacceptable risk135.
Despite the lack of an evidence base, atypical and typical antipsychotics continue to be used 
in clinical practice144, but are associated with increased mortality in the context of clinical 
trials145 and a retrospective database analysis, which ranked haloperidol as carrying the 
highest risk, followed by olanzapine, risperidone and quetiapine144. Such evidence cautions 
against the use of antipsychotics in PD, and highlights the need for further studies in this 
area, as well as the development of new therapeutic approaches for PD psychosis.
Pimavanserin
The therapeutic effect of clozapine in PD psychosis is thought to relate, in part, to blockade 
at the 5-HT2A receptor146. A large double-blind, placebo-controlled study of pimavanserin 
found a significant improvement on the SAPS-PD147, with greater improvement in a 
subgroup with more-pronounced cognitive impairment (Ballard, C. et al., unpublished work, 
see TABLE 3). In an earlier study, a global measure of hallucinations assessed as a 
secondary end point improved in patients treated with pimavanserin, but the reduction in 
visual hallucinations was not significant when considered separately146. The relative lack of 
efficacy of pimavanserin for visual hallucinations suggests that the wider improvement in 
psychotic symptoms is mediated by a different subset of 5-HT receptors than those 
stimulated by lysergic acid diethylamide (LSD), the use of which is associated with 
predominantly visual phenomena. Pimavanserin received FDA approval in April 2016 for 
the treatment of PD psychosis. Its adverse event profile to date suggests advantages over 
other anti-psychotics in terms of risk of stroke, falls, fatigue, blood dyscrasia, neuroleptic 
malignant syndrome, orthostatic hypotension, and worsening of motor symptoms.
Apomorphine
The chemical structure of apomorphine includes a piperidine moiety and, unlike other 
dopamine agonists, this drug exerts intrinsic antagonist effects at the 5-HT2A receptor as 
well as agonist affects at both D1-like and D2-like receptors148. This unique profile might 
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account for case report and open-label study evidence that apomorphine does not exacerbate 
psychosis symptoms and, in some studies, may ameliorate these symptoms149 or improve 
visual contrast sensitivity150. The mode of apomorphine administration may influence its 
impact on psychotic symptoms151. The open-label EUROINF study found improvements in 
perceptual and hallucination symptoms in patients treated with either apomorphine or 
intrajejunal levodopa152. The effect size for apomorphine (0.32) was larger than for 
intrajejunal levodopa (0.29), although the difference was not significant152. Apomophine 
might have a place in the treatment of PD psychosis; however, a better evidence base is 
needed to guide future recommendations148,152,153.
Electroconvulsive therapy
No sham-controlled studies of electroconvulsive therapy (ECT) for PD psychosis have been 
undertaken, but two case series have reported improvements in PD psychosis spectrum 
symptoms. In one study (n = 5), Brief Psychiatric Rating Scale scores improved after five to 
12 ECT sessions, and the effects persisted for 5–30 weeks154. In another study (n = 8), 
SAPS scores improved at 1 week (longer-term data not reported) after a mean of six ECT 
sessions155.
Systemic illness
Psychosis is part of a range of acute events in PD, and is often seen in hospitalized patients 
with systemic infection, dopamine agonist withdrawal syndrome or parkinsonism– 
hyperpyrexia syndrome, as well as in postsurgical states156. Management of the underlying 
precipitant, along with rehydration, cautious use of antipsychotic agents and — in suitable 
cases — gentle introduction of low-dose dopamine agonists, may be required.
Conclusions
The paradigmatic shift in perspective that followed the 2007 consensus definition of PD 
psychosis revitalized research interest and led to a rapidly expanding literature. The impact 
of these studies is still evolving, but there have already been important clinical 
consequences, such as a change in our understanding of the prevalence of PD psychosis, 
given that it increases with PD duration; expansion of the range of symptoms considered 
part of the psychosis spectrum; and recognition of new prospective risk factors for PD 
psychosis. The largest expansion of literature has been in the mechanism domain, 
particularly in studies of cognitive profile, structural brain imaging and genetics.
Despite substantial progress over the past decade, our current state of knowledge leaves key 
questions unanswered (BOX 4). For example, the relationship between PD psychosis, PD-
MCI and PD dementia is unclear. Most patients with PD dementia will have psychosis, but 
only a small proportion of those with PD-MCI have such symptoms. Does this observation 
imply a difference in PD-MCI cognitive profiles for patients with and without psychosis? If 
so, an understanding of these profile differences might help to explain the link between early 
PD psychosis symptoms and the subsequent development of dementia. Another unresolved 
issue is the relationship between individual symptoms in the PD psychosis spectrum in terms 
of underlying pathophysiological mechanisms. Evidence from studies of minor 
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hallucinations, formed hallucinations and delusions, for example, suggest that the 
mechanisms are not the same for all symptoms, with important implications for the 
assessment of PD psychosis in research studies. A continuum assessment scale might be 
helpful in epidemiological and risk factor studies, but may be less useful for studying 
specific symptoms and their underlying mechanism.
Other areas identified as requiring further research include the role of PD medication as a 
modifier or unmasker of psychosis symptoms, motion perception and eye movement control 
deficits associated with passage and presence hallucinations, and the transition from 
hallucinations with insight to those without insight and its impact on quality of life and the 
move to supervised care. These negative outcomes are arguably the most clinically relevant 
aspects of PD psychosis; however, the brain changes that underlie them are unclear.
Finally, visual hallucinations are not unique to synucleinopathies, and patients with eye 
disease, serotonergic dysfunction or AD also have visual symptoms that overlap with those 
of PD but are associated with different cognitive profiles157,158. The progressive 
improvement of visual hallucinations in eye disease contrasts with the progressive 
deterioration in PD and AD psychosis157,158, and comparative studies of brain changes 
associated with visual hallucination susceptibility across clinical contexts might shed light 
on why these differences exist.
Overall, two major themes can be recognized in the literature that has emerged over the past 
decade. One theme highlights the clinical challenges of PD psychosis, with an urgent need 
for better characterization of its symptoms and their impact, and for evidence on how to 
assess and treat these symptoms. The second theme highlights what the psychosis spectrum 
reveals about PD in terms of disease stage and distribution, and its role as a clinical 
biomarker for PD outcomes. Further research in this area will have implications that extend 
beyond the symptoms themselves to the wider issues of cognitive decline in PD, patient and 
carer experience, and the development of novel treatments for positive symptoms in PD and 
other clinical contexts.
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• Parkinson disease (PD) psychosis refers to a spectrum of illusions, 
hallucinations and delusions that occur throughout the disease course
• Evolving literature highlights the importance of recognizing and treating PD 
psychosis, and understanding its role as a clinical biomarker of disease stage, 
distribution and future progression
• Current evidence points to PD psychosis as a set of symptoms with distinct 
pathophysiological mechanisms, as opposed to a single pathophysiological 
symptom with a spectrum of severity
• The relationship between neuropathology in PD psychosis and in vivo 
measures of reduced metabolism, functional MRI alterations and cortical 
volume loss remains unclear
• Further studies are needed to explore the role of PD medication in unmasking 
psychosis symptoms, why psychosis symptoms predict worse cognitive 
outcome, comparisons of psychosis symptoms and mechanisms in different 
clinical conditions, and development of novel treatments
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Figure 1. Regions of cortical atrophy in PD psychosis
The figure summarizes studies that have reported regions of increased atrophy in patients 
with Parkinson disease (PD) psychosis (defined by visual hallucinations in most studies) 
compared with PD controls. The results are superimposed on a lateral view of the right 
hemisphere. The approximate locations of regions of atrophy identified in previous work are 
indicated by circles annotated by the relevant references. The red regions indicate atrophy in 
our own study (ffytche, D. et al., unpublished work), in which PD patients with visual 
hallucinations (n = 8; mean Mini-Mental State Examination (MMSE) score 27.3) were 
compared with PD controls (n = 9; mean MMSE score 29.6). A lenient statistical threshold 
(P < 0.01; 100 contiguous voxels) is used for illustrative purposes. Lighter red shading 
indicates regions deep to the rendered cortical surface. These summary findings indicate that 
visual hallucinations in PD are associated with widely distributed but specific regions of 
cortical atrophy.
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Table 1
Symptoms related to the PD psychosis spectrum
Symptom Phenomenology Association with psychosis spectrum
Isolated diplopia179 Image doubling related to an isolated object or figure — as 
opposed to the whole scene — in the visual environment
May precede the onset of visual hallucinations by 
2–3 years
Freezing180 Walking cessation when passing through narrow spaces Associated with passage hallucinations in PD 
without cognitive impairment
Spatial misjudgement180 Difficulty estimating distance of objects when walking Associated with presence and passage 
hallucinations
PD, Parkinson disease.
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Table 2
Visual and cognitive deficits in the PD psychosis spectrum
Domain Subdomain or task Significant deficit associated with PD psychosis spectrum Minor hallucinations
Unselected PD-MCI MMSE score >25
Visual perception Object Yes51,55,181 Yes47,55 –
Face Yes45 – –
Spatial Yes47,51 – –
Executive function Stroop Yes46,49,182,183 Yes13 –
Go–no-go Yes46,182 Yes13 –
Verbal fluency Yes45,49,182–184; No50 Yes13 No52
Attention – Yes51,181 – No52
Memory Visual Yes45,46,49 Yes47 –
Verbal Yes45,49,184; No50 – No52
‘Yes’ and ‘No’ refer to presence and absence, respectively, of significant deficit reported in studies cited; ‘–’ indicates test not performed. In most 
studies, PD psychosis spectrum was defined by the presence of visual hallucinations. Studies that pooled z-transformed scores from a range of tests 
into a single domain summary (for example, Goldman et al.101) are not included, as individual test scores were lost. Studies using evidence from 
items within global assessment scales such as MOCA (for example, Chung et al.185) or SCOPA-COG (for example, Gallagher et al.55) are also 
excluded. MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PD, Parkinson disease.
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